<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin and soft tissue infections in children &gt;28 days: Evaluation and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin and soft tissue infections in children &gt;28 days: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin and soft tissue infections in children &gt;28 days: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The evaluation and management of suspected <em>Staphylococcus aureus</em> and streptococcal skin and soft tissue infections (SSTIs) in children older than 28 days will be reviewed here. Clinical features of SSTI; the evaluation and management of suspected <em>S. aureus</em> or streptococcal SSTI in neonates; the epidemiology, prevention, and control of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infections in children; and the treatment of invasive MRSA infections in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">"Skin and soft tissue infections in neonates: Evaluation and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p></p><p class="headingAnchor" id="H2218385089"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Methicillin-resistant <em>S. aureus</em> (MRSA) is the most common identifiable cause of skin and soft tissue infection (SSTI) in many communities and should be suspected in most children with SSTI (along with methicillin-susceptible <em>S. aureus</em> [MSSA] and group A <em>Streptococcus</em> [GAS]). The relative frequency of <em>S. aureus</em> compared with GAS depends upon the type of SSTI:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purulent/fluctuant SSTI</strong> – Purulent/fluctuant SSTIs (eg, abscess, furuncle, carbuncle) usually are caused by <em>S. aureus</em> (either MSSA or MRSA). MSSA and MRSA cannot be differentiated clinically or epidemiologically [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis and erysipelas</strong> – Cellulitis is usually caused by GAS and other beta-hemolytic streptococci (groups B, C, G, and F) but also may be caused by <em>S. aureus</em>, particularly in children with risk factors for MRSA  (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>). Erysipelas is usually caused by beta-hemolytic <em>Streptococcus</em>. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a> and  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impetigo and folliculitis</strong> – Impetigo and folliculitis usually are caused by <em>S. aureus</em> (either MSSA or MRSA). (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Staphylococcal folliculitis'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3"><span class="h2">History</span><span class="headingEndMark"> — </span>Important aspects of the history in a child with skin and soft tissue infection (SSTI) include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for community-associated or community-onset health care-associated methicillin-resistant <em>S. aureus </em>(MRSA) infection  (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>) – MRSA isolates in children with health care risk factors are more likely to be resistant to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> and other commonly used drugs than isolates from children without risk factors [<a href="#rid4">4-6</a>]. Perhaps the most important risk factor is living in a community with a high proportion (≥15 percent) of MRSA among community <em>S. aureus</em> isolates. (See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent1">Although past history of MRSA is a risk factor for MRSA, past history of MRSA SSTI does not necessarily mean that the current infection is caused by MRSA [<a href="#rid7">7</a>], particularly if the episodes are separated by &gt;12 months or the child has a predisposing condition, such as eczema [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factors that may suggest pathogens other than <em>S. aureus</em> and group A <em>Streptococcus</em> include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Animal exposure or human or animal bites – May result in polymicrobial infection. (See  <a class="medical medical_review" href="/z/d/html/7674.html" rel="external">"Human bites: Evaluation and management", section on 'Spectrum of antibiotic coverage'</a> and  <a class="medical medical_review" href="/z/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management", section on 'Spectrum of antibiotic coverage'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Travel history – Travel to an endemic area may suggest pathogens such as <em>Corynebacterium diphtheriae.</em> (See  <a class="medical medical_review" href="/z/d/html/3895.html" rel="external">"Skin lesions in the returning traveler"</a> and  <a class="medical medical_review" href="/z/d/html/8051.html" rel="external">"Epidemiology and pathophysiology of diphtheria"</a> and  <a class="medical medical_review" href="/z/d/html/8047.html" rel="external">"Clinical manifestations, diagnosis, and treatment of diphtheria"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hobbies – Hobbies that involve water exposure may increase the risk of pathogens such as <em>Aeromonas</em> or <em>Mycobacterium marinum</em>. (See  <a class="medical medical_review" href="/z/d/html/7646.html" rel="external">"Soft tissue infections following water exposure"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Traumatic lesions, especially those associated with dirt, increase the likelihood of polymicrobial infections including bacteria as well as fungi.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An underlying condition expands the spectrum of pathogens that need to be considered (eg, <em>Pseudomonas aeruginosa</em> in neutropenic patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergy to antibiotics – May affect choice of therapy. (See <a class="local">'Systemic antimicrobial therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Examination</span><span class="headingEndMark"> — </span>Examination determines the type of SSTI. Important aspects of the examination include general appearance (eg, well- or ill-appearing), systemic signs (eg, fever &gt;38°C [100.4°F], hypotension, tachycardia), and the extent of involvement (eg, type, localization, and size of the SSTI).</p><p class="bulletIndent1"><span class="glyph">●</span>Impetigo is a superficial bacterial infection that manifests with lesions that progress from papules to vesicles, pustules, and crusts  (<a class="graphic graphic_picture graphicRef96268 graphicRef63314" href="/z/d/graphic/96268.html" rel="external">picture 1A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folliculitis is a superficial bacterial infection of the hair follicles with purulent material in the epidermis  (<a class="graphic graphic_picture graphicRef50187 graphicRef103500" href="/z/d/graphic/50187.html" rel="external">picture 2A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A skin abscess is a collection of pus within the dermis and deeper skin tissues. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A furuncle (or "boil") is an infection of the hair follicle in which purulent material extends through the dermis into the subcutaneous tissue, where a small abscess forms. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A carbuncle is a coalescence of several inflamed follicles into a single inflammatory mass with purulent drainage from multiple follicles in the epidermis  (<a class="graphic graphic_picture graphicRef70089" href="/z/d/graphic/70089.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erysipelas is an infection of the upper dermis and superficial lymphatics. It is characterized by clear demarcation between involved and uninvolved tissue; the erysipelas lesion is raised above the level of the surrounding skin  (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 4</a>). Patients with erysipelas tend to have acute onset of symptoms with systemic manifestations, including fever and chills. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cellulitis is an infection of the deep dermis and subcutaneous fat without an underlying suppurative focus (eg, cutaneous abscess, septic arthritis, etc); it manifests with erythema, edema, and warmth. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Necrotizing soft tissue infections are characterized by fulminant tissue destruction and systemic signs of toxicity. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7669.html" rel="external">"Primary pyomyositis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxic shock syndrome (staphylococcal or streptococcal) is a clinical illness characterized by rapid onset of fever, rash, hypotension, and multiorgan system involvement; diffuse macular erythroderma is a sign of toxic shock syndrome. (See  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Laboratory evaluation is necessary to determine the microbiologic etiology of SSTI, which may influence treatment decisions. Various bacterial and viral pathogens can cause skin lesions that are clinically indistinguishable from staphylococcal or streptococcal infections; MRSA and methicillin-susceptible <em>S. aureus </em>(MSSA) cannot be differentiated clinically or epidemiologically [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo"</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis"</a> and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram stain, culture, and susceptibility testing of purulent material</strong> – We obtain specimens for Gram stain, culture, and susceptibility testing from patients with purulent skin lesions (abscess, furuncle, carbuncle, draining cellulitis or wound) if purulent material can be obtained [<a href="#rid9">9-11</a>]. Results of these studies guide the choice of empiric and pathogen-directed antimicrobial therapy [<a href="#rid2">2,7,12,13</a>]. It is particularly important to obtain wound cultures from immunocompromised patients and those with severe local infections, systemic signs of infection, recurrent or multiple abscesses, an epidemiologic link to individuals with MRSA infection, and those who have failed initial treatment [<a href="#rid9">9,14</a>].</p><p></p><p class="bulletIndent1">The Gram stain may help to guide empiric therapy. Gram stain identification of gram-positive cocci in clusters provides early indication of staphylococcal infection. Gram stain identification of gram-positive cocci in chains provides early identification of streptococcal infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood culture</strong> – We obtain blood cultures from patients who have signs of serious systemic infection (eg, prolonged fever, tachycardia, hypotension), neutropenia or severe cell-mediated immunodeficiency, animal bites, or immersion injuries [<a href="#rid3">3,14,15</a>].</p><p></p><p class="bulletIndent1">In a retrospective review, blood cultures were positive in 12.5 percent of immunocompetent children hospitalized with complicated SSTI (defined as surgical or traumatic wound infection, SSTI requiring surgical intervention [other than routine incision and drainage], or infected ulcer or burn), and none of those with uncomplicated SSTI [<a href="#rid16">16</a>]. In observational studies, blood cultures are rarely positive in children with uncomplicated SSTI [<a href="#rid17">17,18</a>]. In a retrospective review of data from 38 hospitals between 2012 and 2018, blood cultures were positive in only 0.6 percent of emergency department encounters and 1 percent of hospitalization encounters for children with SSTIs who had a blood culture obtained [<a href="#rid19">19</a>]. In addition, blood cultures may be positive for contaminants, which may necessitate follow-up cultures or prolong intravenous antibiotic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Susceptibility testing</strong> – If <em>S. aureus</em> is isolated in bacterial culture, susceptibility testing is necessary to distinguish MRSA from MSSA [<a href="#rid1">1</a>]. In some laboratories, methicillin resistance may be detected rapidly using commercially available molecular tests for the <em>mecA</em> gene that leads to methicillin resistance. (See  <a class="medical medical_review" href="/z/d/html/3166.html" rel="external">"Rapid detection of methicillin-resistant Staphylococcus aureus"</a>.)</p><p></p><p class="bulletIndent1">Susceptibility testing is important in monitoring the local proportion of <em>S. aureus</em> infections caused by MRSA and the prevalence of resistance to various classes of antimicrobials [<a href="#rid2">2,9,12,20</a>]. <em>S. aureus</em> isolates associated with SSTI should be tested for susceptibility to beta-lactam antibiotics, <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a>, tetracyclines, <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a>, and possibly <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a> [<a href="#rid21">21</a>]; isolates associated with SSTI requiring parenteral therapy also should be tested for susceptibility to <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> in selected circumstances (eg, high rates of clindamycin resistance, children with renal dysfunction, inflammatory bowel disease, <em>Clostridioides difficile</em>-associated disease, or intolerance to vancomycin). A D test or automated test for inducible resistance to clindamycin should be performed on isolates that are resistant to erythromycin but susceptible to clindamycin if clindamycin therapy is being considered. (See <a class="local">'Treatment setting'</a> below and  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Microbiologic characteristics'</a> and  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Inducible clindamycin resistance testing'</a>.)</p><p></p><p class="bulletIndent1">Beta-hemolytic <em>Streptococcus</em> usually is susceptible to penicillin and other beta-lactam antibiotics; susceptibility testing is not necessary. (See  <a class="medical medical_review" href="/z/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children", section on 'Treatment of initial episodes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal cultures</strong> – We do not obtain routine nasal cultures from patients presenting with possible MRSA infection [<a href="#rid9">9</a>]. The predictive value of screening for colonization is not known [<a href="#rid22">22</a>]. In addition, nasal and wound isolates may be discordant with respect to antimicrobial susceptibility and pulsed-field gel electrophoresis [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT APPROACH</span><span class="headingEndMark"> — </span>The discussion below focuses on the management of purulent/fluctuant skin and soft tissue (SSTI), cellulitis, erysipelas, and superficial SSTI in children. The management of muscle infections and necrotizing soft tissue infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7669.html" rel="external">"Primary pyomyositis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Treatment'</a>.)</p><p>The management of invasive SSTI (ie, SSTI that extend beyond the skin and soft tissues) is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">"Staphylococcus aureus bacteremia in children: Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/6068.html" rel="external">"Invasive group A streptococcal infections in children"</a> and  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Empiric antimicrobial therapy'</a>.)</p><p>Our approach to management is largely consistent with guidelines provided by the American Academy of Pediatrics Committee on Infectious Diseases and the Infectious Diseases Society of America  (<a class="graphic graphic_algorithm graphicRef113304" href="/z/d/graphic/113304.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef113303" href="/z/d/graphic/113303.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef131685" href="/z/d/graphic/131685.html" rel="external">algorithm 3</a>) [<a href="#rid3">3,10,11</a>].</p><p class="headingAnchor" id="H1464923112"><span class="h2">SSTI and hemodynamic instability</span><span class="headingEndMark"> — </span>Children with localized skin infections and associated hemodynamic instability generally have either a systemic infection or toxic shock syndrome. Treatment of toxic shock syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention", section on 'Streptococcal toxic shock syndrome'</a>.)</p><p>For activity against <em>S. aureus</em> and group A <em>Streptococcus</em> (GAS) in hemodynamically unstable children with SSTI, we suggest an empiric parenteral regimen of <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> <strong>plus</strong> either <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a>  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>); additional activity against gram-negative pathogens may be necessary. The combination of vancomycin and nafcillin or oxacillin is necessary to maximize coverage for both methicillin-resistant <em>S. aureus </em>(MRSA) and methicillin-susceptible <em>S. aureus </em>(MSSA), as well as beta-hemolytic <em>Streptococcus</em>. We do not add <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> for synergy; the potential risk of nephrotoxicity with even low-doses of gentamicin outweighs the theoretic benefit [<a href="#rid24">24</a>]. (See <a class="local">'Considerations for antibiotic selection'</a> below.)</p><p>For children who are unable to receive penicillin antibiotics, monotherapy with parenteral <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> or <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a> is an alternative; <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> is an alternative for children without a history of anaphylaxis to penicillin or cephalosporin antibiotics. Consultation with an expert in infectious diseases is suggested. The role of ceftaroline in critically ill children with SSTI remains to be determined. It provides an important option in communities with high rates of <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> resistance; health care-associated SSTIs with onset in the community or the hospital; and children with renal dysfunction, inflammatory bowel disease, <em>C. difficile</em>-associated disease, or intolerance to <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>.</p><p class="headingAnchor" id="H3218989142"><span class="h2">Purulent/fluctuant SSTI</span><span class="headingEndMark"> — </span>Skin abscesses, furuncles, and carbuncles are purulent/fluctuant SSTI. Cellulitis also may be associated with purulent drainage or exudate in the absence of a drainable abscess (sometimes called purulent cellulitis, although the terminology for this clinical constellation is inconsistent) [<a href="#rid3">3,10</a>]. Purulent/fluctuant SSTI usually are caused by <em>S. aureus</em>. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H4040691374"><span class="h3">Drainage</span><span class="headingEndMark"> — </span>We recommend incision and drainage of purulent and fluctuant lesions  (<a class="graphic graphic_algorithm graphicRef113304" href="/z/d/graphic/113304.html" rel="external">algorithm 1</a>). Point-of-care ultrasonography may be helpful in identifying lesions appropriate for incision and drainage (eg, abscess) [<a href="#rid25">25</a>]. Application of moist heat may help to promote drainage of small furuncles that are not amenable to incision and drainage [<a href="#rid3">3,12</a>]. Although drainage is the mainstay of therapy, we also typically administer adjunctive antibiotics  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>). (See <a class="local">'Systemic antimicrobial therapy'</a> below.)</p><p>Children with cardiac conditions predisposing to adverse outcomes from infectious endocarditis (eg, unrepaired cyanotic congenital heart disease, repaired congenital heart defects with prosthetic defects, etc) should receive prophylactic antibiotics before incision and drainage. (See  <a class="medical medical_review" href="/z/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a> and  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p>Purulent fluid should be sent for Gram stain, culture, and susceptibility testing [<a href="#rid11">11</a>]. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p>Drainage is the mainstay of therapy for purulent SSTI [<a href="#rid3">3,10,26</a>]. For purulent/fluctuant SSTI that are &lt;5 cm (2 inches) in diameter (including surrounding erythema/cellulitis) in children ≥9 years and &lt;4 cm (1.6 inches) in children 12 months through 8 years, drainage appears to be more important than antimicrobial therapy [<a href="#rid27">27-29</a>]. The effectiveness of drainage for purulent SSTI is supported by a meta-analysis of four randomized trials in which most patients (&gt;83 percent) achieved successful outcomes whether they were assigned to antibiotic therapy or placebo after incision and drainage [<a href="#rid30">30</a>]. In additional randomized and observational studies, most patients with uncomplicated MRSA skin abscesses who underwent incision and drainage or spontaneous drainage improved despite adjunctive antibiotics ineffective against MRSA [<a href="#rid28">28,31-34</a>]. Nonetheless, adjunctive antibiotics are beneficial in preventing recurrence, subsequent drainage procedures, and secondary spread [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2677985812"><span class="h3">Adjunctive antibiotics</span><span class="headingEndMark"> — </span>Although drainage is the mainstay of therapy for purulent SSTI, adjunctive antibiotics are also typically administered  (<a class="graphic graphic_algorithm graphicRef113304" href="/z/d/graphic/113304.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). Adjunctive antibiotics are associated with clinical improvement and may prevent recurrence, subsequent drainage, and secondary spread [<a href="#rid30">30,35,36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For hemodynamically stable children with purulent/fluctuant SSTI of the face, hand, or perineum and hemodynamically stable children from communities in which ≥10 to 15 percent of <em>S. aureus</em> isolates are MRSA, we provide initial coverage for MRSA. <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a>, <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a>, and <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) are options for oral therapy; clindamycin and <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> are options for initial parenteral therapy  (<a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). The choice of initial empiric therapy should be determined by local susceptibility patterns.</p><p></p><p class="bulletIndent1">Second-line parenteral agents include <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a>, <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a>, <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a>, <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">tedizolid</a> (for children ≥12 years of age), <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a> (for children ≥18 years of age), and <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> (for children ≥18 years of age). Among these, we prefer ceftaroline or linezolid. Although experience with dalbavancin in children is limited, it may be reasonable for children who would not be able to complete therapy with an oral agent. However, second-line parenteral agents are rarely used because of cost. (See <a class="local">'Systemic antimicrobial therapy'</a> below.)</p><p></p><p class="bulletIndent1">In a multicenter randomized trial, TMP-SMX and <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> were similarly efficacious in the treatment of uncomplicated SSTI in children and adults (with cure rates of 80 to 90 percent in both treatment arms) [<a href="#rid37">37</a>]. Trials comparing clindamycin or TMP-SMX with <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> are lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For hemodynamically stable children with purulent/fluctuant SSTI that do not involve the face, hand, or perineum and who are from communities in which &lt;10 to 15 percent of <em>S. aureus </em>isolates are MRSA, we provide coverage for MSSA. <a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">Cefuroxime</a>, <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">cephalexin</a>, <a class="drug drug_pediatric" data-topicid="13227" href="/z/d/drug information/13227.html" rel="external">dicloxacillin</a>, and <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a> (not available in the United States) are options for oral therapy. Among these, we prefer cephalexin because of its narrow spectrum and three times a day dosing. We tend to avoid dicloxacillin because it must be given four times per day and the oral suspension is not well tolerated by children  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>). <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a>, TMP-SMX, and <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> are alternatives for children who are unable to receive penicillin and cephalosporin antibiotics.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">Cefazolin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>, and <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> are options for parenteral therapy. (See <a class="local">'Considerations for antibiotic selection'</a> below.)</p><p></p><p>Adjunctive antibiotics are particularly important for children with [<a href="#rid3">3,10,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic signs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying medical problems that increase the risk of poor response or complications (eg, primary immune deficiency, diabetes mellitus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple sites of infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;12 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesions ≥5 cm (2 inches) in diameter (including surrounding erythema/cellulitis) in children age ≥9 years and ≥4 cm (1.6 inches) in diameter in children age 12 months through 8 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesions of the face, hand, or perineum (which are difficult to drain)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesions near an implanted device</p><p></p><p>Most strains of MRSA that cause SSTI in the community are relatively susceptible to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, TMP-SMX, and <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> [<a href="#rid38">38-40</a>]. However, given temporal and geographic variability [<a href="#rid41">41,42</a>] and the challenges of distinguishing true community-onset infections from community-onset health care-associated infections, empiric therapy should be determined by local resistance patterns. Some strains are resistant to one or more of these antibiotics, and some have susceptibility patterns similar to nosocomial isolates [<a href="#rid43">43-46</a>]. We do not use fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">ciprofloxacin</a>) or macrolides (eg, <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a>, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>) for the treatment of MRSA SSTI because community isolates of MRSA are relatively resistant to them [<a href="#rid47">47,48</a>].</p><p>In a meta-analysis of four randomized trials (including 2406 participants) of patients who underwent drainage for a skin or soft tissue abscess [<a href="#rid26">26,27,29,49</a>], fewer patients receiving adjunctive antibiotics than placebo had treatment failure (7.7 versus 16.1 percent, calculated risk difference 7.4 percent, 95% CI 2.8-12.1 percent) or developed new lesions within 10 to 30 days (6.2 versus 15.3 percent, calculated risk difference 10 percent, 95% CI 7.2-12.8 percent) [<a href="#rid30">30</a>]. Although the rate of adverse events was increased among antibiotic recipients (calculated risk difference 4.4 percent, 95% CI 1.0-7.8 percent), most of the adverse events were mild (eg, gastrointestinal symptoms, mild rashes).</p><p>Other randomized trials [<a href="#rid37">37,50,51</a>] and observational studies [<a href="#rid13">13,28,52-54</a>] suggest that, in addition to incision and drainage as indicated, appropriate antimicrobial therapy is associated with clinical improvement, particularly for children with lesions ≥4 to 5 cm (1.6 to 2 inches) in diameter, depending on age, but even for smaller lesions. The effect of adjunctive antimicrobial therapy on secondary spread has not been well studied, but there is some evidence to suggest that adjunctive antibiotics are beneficial in preventing secondary spread [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H4160090292"><span class="h2">Cellulitis</span><span class="headingEndMark"> — </span>Antimicrobial therapy is the cornerstone of therapy for typical (nonpurulent) cellulitis  (<a class="graphic graphic_algorithm graphicRef113303" href="/z/d/graphic/113303.html" rel="external">algorithm 2</a>). Typical cellulitis usually is caused by beta-hemolytic streptococci, particularly GAS, but also may be caused by <em>S. aureus</em>. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for MRSA</strong> – For hemodynamically stable children with typical cellulitis and risk factors for MRSA  (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>), we provide initial coverage for both beta-hemolytic<em> Streptococcus</em> and MRSA.</p><p></p><p class="bulletIndent1">Options for oral therapy include monotherapy with <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> or combination therapy with a beta-lactam antibiotic (eg, <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">cephalexin</a>) plus either TMP-SMX or <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a>. Among these, we prefer monotherapy with clindamycin unless the local prevalence of clindamycin-resistant <em>S. aureus</em> is ≥15 percent  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Options for parenteral therapy include <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> and <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>. <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">Linezolid</a>, <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a>, <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, or <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> is also available for children with complicated SSTI. <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">Tedizolid</a> is available for children ≥12 years [<a href="#rid55">55</a>], but its use is limited by cost. (See <a class="local">'Considerations for antibiotic selection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No risk factors for MRSA</strong> – For hemodynamically stable children with typical cellulitis and no risk factors for<strong> MRSA </strong> (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>), we provide initial coverage for both beta-hemolytic<em> Streptococcus</em> and MSSA. We broaden coverage to include MRSA if initial therapy is unsuccessful. (See <a class="local">'Failure to respond'</a> below.)</p><p></p><p class="bulletIndent1">First-generation cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">cephalexin</a>, <a class="drug drug_pediatric" data-topicid="13123" href="/z/d/drug information/13123.html" rel="external">cefadroxil</a>), second-generation cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">cefuroxime</a>), <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a> (not available in the United States), and <a class="drug drug_pediatric" data-topicid="13227" href="/z/d/drug information/13227.html" rel="external">dicloxacillin</a> are options for oral therapy. Among these, we prefer cephalexin because of its narrow spectrum and three times a day dosing; the oral suspension of dicloxacillin is poorly tolerated by children. We also tend to avoid dicloxacillin because it must be given four times per day  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>) [<a href="#rid56">56</a>]. <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a> is an alternative for children who are unable to receive penicillin or cephalosporin antibiotics.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">Cefazolin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>, and <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> are options for parenteral therapy. (See <a class="local">'Considerations for antibiotic selection'</a> below.)</p><p></p><p class="bulletIndent1">For patients with cellulitis and no risk factors for MRSA, it is not necessary to provide empiric coverage for MRSA. In a multicenter randomized trial in 153 patients (predominantly adults) with nonpurulent cellulitis, the cure rates were comparable among those treated with <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">cephalexin</a> (82 percent) and combination cephalexin/TMP-SMX (85 percent) [<a href="#rid57">57</a>]. In another multicenter trial, 500 patients &gt;12 years of age with nonpurulent cellulitis were randomly assigned to empiric treatment with cephalexin plus either TMP-SMX or placebo [<a href="#rid58">58</a>]. Cure rates at 14 to 21 days did not differ between groups, although the results were imprecise (76.2 versus 69 percent, difference 7.3 percent, 95% CI -1.0 to 15.5).</p><p></p><p class="headingAnchor" id="H3755615323"><span class="h2">Erysipelas</span><span class="headingEndMark"> — </span>Antimicrobial therapy is the cornerstone of therapy for erysipelas  (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 4</a>). For children with erysipelas, we provide antimicrobial coverage for beta-hemolytic <em>Streptococcus </em> (<a class="graphic graphic_algorithm graphicRef131685" href="/z/d/graphic/131685.html" rel="external">algorithm 3</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). Options for oral therapy include <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> and penicillin; <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">cephalexin</a> and <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> are alternatives. Options for parenteral therapy include <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">cefazolin</a>, <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>, <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a>, and <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>. Clindamycin is an alternative for children who cannot receive penicillin or cephalosporin antibiotics. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p class="headingAnchor" id="H187876654"><span class="h2">Impetigo or folliculitis</span><span class="headingEndMark"> — </span>Impetigo and folliculitis are superficial SSTI. For localized, superficial SSTI in children without systemic symptoms, we provide outpatient management with topical antibiotics (eg, <a class="drug drug_pediatric" data-topicid="12622" href="/z/d/drug information/12622.html" rel="external">mupirocin</a>) [<a href="#rid3">3,10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Limited impetigo'</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Staphylococcal folliculitis'</a>.)</p><p>For superficial SSTI that involves <strong>multiple</strong> sites, we provide oral antimicrobial therapy that includes coverage for both <em>S. aureus</em> and beta-hemolytic <em>Streptococcus</em>. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Extensive impetigo and ecthyma'</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Staphylococcal folliculitis'</a>.)</p><p class="headingAnchor" id="H2086253651"><span class="h1">SYSTEMIC ANTIMICROBIAL THERAPY</span></p><p class="headingAnchor" id="H4196170145"><span class="h2">Treatment setting</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalization for parenteral therapy</strong> – We generally hospitalize the following children with skin and soft tissue infection (SSTI) for parenteral antimicrobial therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic signs, including fever (&gt;38°C [100.4°F]), tachycardia, hypotension, or systemic inflammatory response syndrome (see  <a class="medical medical_review" href="/z/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Systemic inflammatory response syndrome'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid progression of erythema</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limb-threatening infection (eg, necrotizing soft tissue infection, pyomyositis) (see  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with underlying medical problems that may be associated with poor response or complications (eg, malignancy, primary immune deficiency, diabetes mellitus)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children who are unable to tolerate oral medications</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with SSTI close to an implanted device</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial parenteral therapy in emergency department or "short stay" unit</strong> – We usually provide the first one or two doses of antimicrobial therapy parenterally (eg, in an emergency department observation or "short stay" unit if one is available) for SSTI in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children (of any age) with multiple sites of nonsuperficial infection (ie, infections other than impetigo or folliculitis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;5 years with abscesses on the face or perineum</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children age 29 days through 11 months with SSTI ≥3 cm (1.2 inches) in diameter (including surrounding erythema/cellulitis) or age 12 months through 4 years with SSTI ≥4 cm (1.6 inches) in diameter</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient oral therapy</strong> – We typically initiate antimicrobial therapy orally for children with indications for antimicrobial therapy who do not meet the above criteria for hospitalization or initial parenteral therapy.</p><p></p><p class="headingAnchor" id="H1550801307"><span class="h2">Considerations for antibiotic selection</span><span class="headingEndMark"> — </span>The choice of the initial antimicrobial regimen is guided by clinical features, desired spectrum of coverage, and local <em>S. aureus</em> susceptibility data  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>) [<a href="#rid10">10,11,21,59</a>]. Information regarding local susceptibility patterns can be obtained from local public health officials or hospital laboratories. In several geographic areas of the United States (Northeast, West), resistance to <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> increased among methicillin-resistant <em>S. aureus </em>(MRSA) isolates between 2012 and 2018 [<a href="#rid60">60</a>]. When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated.</p><p>In vitro susceptibility studies, observational studies, and randomized trials support the effectiveness of beta-lactam antibiotics (eg, penicillins, cephalosporins) [<a href="#rid57">57,58,61-66</a>], <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> [<a href="#rid30">30,35,37,43,50,67,68</a>], <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) [<a href="#rid4">4,30,37,47,54,68,69</a>], <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a>/<a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> [<a href="#rid31">31,70,71</a>], <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> [<a href="#rid72">72-74</a>], <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> [<a href="#rid73">73-78</a>], <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> [<a href="#rid79">79-81</a>], <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, and <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> [<a href="#rid82">82,83</a>] for the treatment of SSTI in children [<a href="#rid84">84</a>]. Few studies have directly compared one of these agents with another.</p><p>Factors that may help in choosing among antimicrobial regimens that provide adequate coverage for <em>S. aureus</em> and/or beta-hemolytic <em>Streptococcus</em> include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial stewardship</strong> – When multiple therapeutic options are available for empiric therapy, the option with the narrowest therapeutic range should be prioritized [<a href="#rid85">85</a>]. When the etiologic agent and susceptibility are known, antimicrobial therapy can be further narrowed as indicated.</p><p></p><p class="bulletIndent1">Avoiding <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a>, <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">tedizolid</a>, <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a>, <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, and <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> when the isolate is methicillin-susceptible and the patient is not allergic to beta-lactam antibiotics may help to minimize promotion of resistance to these drugs, which are crucial to the treatment of invasive infections [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'MRSA infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local prevalence of clindamycin-resistant </strong><strong><em>S. aureus</em></strong> – Avoidance of <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> may be warranted if the prevalence of clindamycin-resistant <em>S. aureus</em> is ≥15 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ability of the child to swallow pills and palatability of liquid antibiotics</strong> – Therapeutic options may be limited if the child cannot swallow pills. Adherence to oral therapy may be challenging if oral solutions are unpalatable [<a href="#rid56">56</a>]. Flavoring can be can be added to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> solution to overcome the unpleasant taste [<a href="#rid86">86,87</a>]; alternately, the contents of clindamycin capsules can be emptied into a small amount of chocolate syrup, applesauce, or yogurt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age of the child</strong> – <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">Tetracycline</a> antibiotics may cause permanent tooth discoloration if used repeatedly for children &lt;8 years. However, <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> binds less readily to calcium than other tetracycline antibiotics and, in some studies, was not associated with visible teeth staining in children &lt;8 years [<a href="#rid88">88-91</a>]. Thus, doxycycline may be used for ≤21 days in children of all ages [<a href="#rid91">91</a>]. <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">Tedizolid</a> is available only for children ≥12 years of age [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cost, adverse effects, and clinical experience</strong> – The use of <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> for SSTI is limited by cost and toxicity (bone marrow suppression, peripheral and optic neuropathy) if used for a prolonged time [<a href="#rid10">10,92</a>]. The use of <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">tedizolid</a> and <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> is also limited by cost. These agents should be reserved for those who do not respond to or cannot tolerate other agents or whose isolates are resistant to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> and TMP-SMX.</p><p></p><p class="bulletIndent1">Clinical experience with <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a>, <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, <a class="drug drug_pediatric" data-topicid="128933" href="/z/d/drug information/128933.html" rel="external">tedizolid</a>, and <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> in children with SSTI is limited and their role remains to be determined. Nonetheless, they provide an important option in communities with high rates of <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> resistance; health care-associated SSTIs with onset in the community or the hospital; and children with renal dysfunction, inflammatory bowel disease, <em>C. difficile</em>-associated disease, or intolerance to <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>. Dalbavancin may be an attractive option for management of children for whom completing therapy with an oral antibiotic is challenging for some reason, such as children with short bowel syndrome or those requiring parenteral nutrition.</p><p></p><p class="headingAnchor" id="H3858210190"><span class="h2">Switching from parenteral to oral therapy</span><span class="headingEndMark"> — </span>Results of antibiotic susceptibility testing should be used to make decisions about which oral antibiotic to use for continuation of systemic therapy  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>). For children with negative cultures or in whom cultures were not obtained, we usually continue/initiate <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> for children with nonpurulent SSTI and continue clindamycin or switch to TMP-SMX for children purulent/fluctuant SSTI.</p><p>For children with systemic signs and underlying medical problems that increase the risk of poor response or complications (eg, malignancies, primary immune deficiency, diabetes mellitus), we continue parenteral therapy at least until all of the following criteria are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of systemic symptoms and fever</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in other clinical findings (see <a class="local">'Monitoring response'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic susceptibility results are available</p><p class="bulletIndent1"><span class="glyph">●</span>Child is able to tolerate an oral agent</p><p></p><p>For children with multiple sites of infection, children &lt;5 years with abscesses of the face or perineum, and children age 29 days through 11 months in children with SSTI ≥3 cm (1.2 inches) in diameter (including surrounding erythema/cellulitis) or age 12 months through 4 years with SSTI ≥4 cm (1.6 inches), we switch to oral therapy after one or two doses of parenteral therapy provided that the child is well-appearing, able to tolerate oral medications, and able to adhere to oral regimen and follow-up plans.</p><p class="headingAnchor" id="H3054258073"><span class="h2">Total duration</span><span class="headingEndMark"> — </span>The total duration of systemic therapy for staphylococcal or streptococcal SSTI is not well studied. It depends upon the antimicrobial agent, clinical syndrome, and clinical response.</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics other than <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> – For antibiotics other than dalbavancin, a duration of five days is generally adequate for purulent/fluctuant SSTI, cellulitis, erysipelas, impetigo, and folliculitis, provided the patient improves clinically and the course is uncomplicated. The duration may be extended if the clinical response is inadequate or complications develop.</p><p></p><p class="bulletIndent1">Our suggested five-day course of therapy for uncomplicated SSTI in children treated with antibiotics other than <a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">dalbavancin</a> is supported by stratified analysis of randomized trial that compared 3 with 10 days of antibiotic therapy (TMP-SMX) following surgical drainage of uncomplicated skin abscess [<a href="#rid93">93</a>]. Children with MRSA infection who were assigned to three days of therapy had increased rates of treatment failure, defined as persistent or increased size of the original abscess requiring additional antibiotic therapy or surgical incision and drainage and one-month recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="121651" href="/z/d/drug information/121651.html" rel="external">Dalbavancin</a> – For children &lt;18 years of age, dalbavancin is given in a single intravenous dose. Its effective half-life is approximately nine days [<a href="#rid82">82,94</a>].</p><p></p><p class="headingAnchor" id="H19"><span class="h1">RESPONSE TO THERAPY</span></p><p class="headingAnchor" id="H2985801431"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>Response to therapy is indicated by clinical improvement after 48 hours. In children who are admitted to the hospital for antimicrobial therapy, we monitor the skin and soft tissue infection (SSTI) for improvement or progression, the patient's vital signs, and culture and susceptibility results (if obtained).</p><p>Children who are treated for SSTI in the outpatient setting should be instructed to seek medical care promptly if they develop systemic symptoms or if local symptoms worsen [<a href="#rid12">12</a>]. They should be seen for follow-up within 48 hours (whether or not antimicrobial therapy is prescribed). Follow-up is essential to ensure clinical improvement and determine the need for additional drainage or change in antimicrobial therapy [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Failure to respond</span><span class="headingEndMark"> — </span>Additional drainage procedures and/or initiation of or change in antimicrobial therapy (guided by culture and susceptibility results, if available) may be warranted for patients who have not improved after 48 hours of observation or antimicrobial therapy  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a>). Patients with purulent/fluctuant lesions who did not respond to incision and drainage alone should be treated with antibiotics; repeat incision and drainage also may be warranted.</p><p>Possible explanations for failure to respond in patients receiving an agent to which their isolate is susceptible include inadequate drainage (if drainage was performed), reformation of the abscess, development of a new abscess, or poor compliance with oral therapy. Ultrasonography may identify residual, recurrent, or new abscesses that require drainage [<a href="#rid25">25</a>].</p><p>If cultures remain negative and new or reformed abscesses are not identified, a change to second-line empiric therapy may be indicated  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H21"><span class="h2">Recurrence</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purulent infection</strong> – Reported recurrence rates for methicillin-resistant <em>S. aureus </em>(MRSA) SSTI range from 19 to 63 percent, even after successful treatment [<a href="#rid23">23,96-99</a>]. It is important to look for local predisposing conditions (eg, pilonidal cyst, hidradenitis suppurativa, foreign material) in children who have recurrent SSTI at the same site. (See  <a class="medical medical_review" href="/z/d/html/87056.html" rel="external">"Pilonidal disease", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Recurrence is usually treated in the same way as the initial episode. In a retrospective analysis of 264 MRSA isolates from 105 otherwise healthy children (birth to 18 years) with recurrent MRSA SSTI, 90 percent of recurrent infections were caused by a strain identical to that in the previous episode [<a href="#rid100">100</a>]. Strategies to eliminate colonization are sometimes used, but the effectiveness of this approach in reducing recurrences is not clear [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control", section on 'Children with recurrent MRSA infection'</a>.)</p><p></p><p class="bulletIndent1">For patients with recurrent infection due to <em>S. aureus</em>, attempting decolonization is reasonable. (See  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control", section on 'Children with recurrent MRSA infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpurulent infection</strong> – Recurrences occur in approximately 14 percent of cellulitis cases within one year and 45 percent of cases within three years, usually in the same location [<a href="#rid102">102</a>]. Conditions that predispose to recurrent cellulitis include obesity, immunosuppression, edema due to impaired lymphatic drainage, venous insufficiency, and tinea pedis [<a href="#rid103">103-111</a>].</p><p></p><p class="bulletIndent1">Management of recurrent cellulitis includes evaluation for alternative diagnoses. Predisposing conditions should be identified and alleviated if possible. The approach to antimicrobial therapy for recurrent cellulitis is the same as that for the initial episode. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H3544692359"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Patient education regarding methods to prevent spread of infection to others is an essential component of management of methicillin-resistant <em>S. aureus</em> skin and soft tissue infection [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control", section on 'Prevention in the community'</a>.)</p><p class="headingAnchor" id="H887384669"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">"Society guideline links: Management of <i>Staphylococcus aureus</i> infection"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15481.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4025.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Purulent/fluctuant skin and soft tissue infections (SSTI) usually are caused by <em>Staphylococcus aureus</em> (either methicillin-susceptible <em>S. aureus</em> [MSSA] or methicillin-resistant <em>S. aureus</em> [MRSA]). Cellulitis is usually caused by group A <em>Streptococcus</em> and other beta-hemolytic streptococci, but also may be caused by <em>S. aureus</em>, particularly in children with risk factors for MRSA  (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>). Erysipelas is usually caused by beta-hemolytic <em>Streptococcus</em>. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The history and examination of a child with suspected <em>S. aureus</em> or streptococcal SSTI focuses on risk factors for MRSA  (<a class="graphic graphic_table graphicRef113301" href="/z/d/graphic/113301.html" rel="external">table 1</a>), factors predisposing to infection with other pathogens, the type and extent of SSTI (eg, abscess  (<a class="graphic graphic_picture graphicRef53261" href="/z/d/graphic/53261.html" rel="external">picture 5</a>), furuncle, carbuncle  (<a class="graphic graphic_picture graphicRef70089" href="/z/d/graphic/70089.html" rel="external">picture 3</a>), cellulitis, erysipelas  (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 4</a>), impetigo  (<a class="graphic graphic_picture graphicRef63314" href="/z/d/graphic/63314.html" rel="external">picture 1B</a>)), and associated systemic signs (eg, fever &gt;38°C [100.4°F], hypotension, tachycardia). (See <a class="local">'History'</a> above and <a class="local">'Examination'</a> above.)</p><p></p><p class="bulletIndent1">Laboratory evaluation is necessary to determine the microbiologic etiology of SSTI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain specimens for Gram stain, culture, and susceptibility testing from patients with purulent skin lesions (abscess, furuncle, carbuncle, draining cellulitis or wound) if purulent material can be obtained.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain blood cultures from patients with signs of serious systemic infection (eg, prolonged fever, tachycardia, hypotension), neutropenia or immunodeficiency, animal bites, or immersion injuries.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not obtain routine nasal cultures from children presenting with possible MRSA SSTI. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Our approach to the management of suspected <em>S. aureus</em> or streptococcal SSTI in children varies with the clinical status of the child and the type of SSTI  (<a class="graphic graphic_algorithm graphicRef113304" href="/z/d/graphic/113304.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef113303" href="/z/d/graphic/113303.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef131685" href="/z/d/graphic/131685.html" rel="external">algorithm 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with SSTI and hemodynamic instability, we suggest initial parenteral antimicrobial coverage for MRSA, MSSA, and beta-hemolytic <em>Streptococcus </em> (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); additional coverage for gram-negative pathogens may be necessary. (See <a class="local">'SSTI and hemodynamic instability'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most hemodynamically stable children with purulent/fluctuant SSTI, we suggest adjunctive antibiotic therapy in addition to drainage rather than drainage alone  (<a class="graphic graphic_algorithm graphicRef113304" href="/z/d/graphic/113304.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Purulent/fluctuant SSTI'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For hemodynamically stable children with cellulitis and no risk factors for MRSA, we provide empiric antimicrobial coverage for beta-hemolytic <em>Streptococcus</em> and MSSA  (<a class="graphic graphic_algorithm graphicRef113303" href="/z/d/graphic/113303.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). For children with risk factors for MRSA, we provide empiric antimicrobial coverage for beta-hemolytic <em>Streptococcus</em> and MRSA  (<a class="graphic graphic_algorithm graphicRef113303" href="/z/d/graphic/113303.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). (See <a class="local">'Cellulitis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For hemodynamically stable children with erysipelas, we provide empiric antimicrobial coverage for beta-hemolytic <em>Streptococcus </em> (<a class="graphic graphic_algorithm graphicRef131685" href="/z/d/graphic/131685.html" rel="external">algorithm 3</a> and <a class="graphic graphic_table graphicRef113299" href="/z/d/graphic/113299.html" rel="external">table 3A</a>). (See <a class="local">'Erysipelas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with localized impetigo or folliculitis and no systemic signs (fever, hypotension, tachycardia), we provide topical antibiotic therapy. For children with multiple sites of impetigo or folliculitis, we provide systemic antimicrobial therapy. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Staphylococcal folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – Response to therapy is indicated by clinical improvement after 48 hours. Additional drainage procedures and/or change in or initiation of antimicrobial therapy (guided by culture and susceptibility results, if available) may be warranted for patients who have not improved after 48 hours of observation or antimicrobial therapy or observation if adjunctive antibiotics were not administered initially  (<a class="graphic graphic_table graphicRef113302" href="/z/d/graphic/113302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef113299 graphicRef129344" href="/z/d/graphic/113299.html" rel="external">table 3A-B</a>). (See <a class="local">'Response to therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.</a></li><li><a class="nounderline abstract_t">Heilpern KL. Skin and soft tissue abscesses: the case for culturing abscess fluid. Ann Emerg Med 2007; 50:64.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980.</a></li><li><a class="nounderline abstract_t">Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.</a></li><li><a class="nounderline abstract_t">Hultén KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.</a></li><li><a class="nounderline abstract_t">Patel AB, Hill E, Simpson EL, Hanifin JM. Reversion of methicillin-resistant Staphylococcus aureus skin infections to methicillin-susceptible isolates. JAMA Dermatol 2013; 149:1167.</a></li><li><a class="nounderline abstract_t">Bocchini CE, Mason EO, Hulten KG, et al. Recurrent community-associated Staphylococcus aureus infections in children presenting to Texas Children's Hospital in Houston, Texas. Pediatr Infect Dis J 2013; 32:1189.</a></li><li class="breakAll">Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on January 23, 2008).</li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li class="breakAll">American Academy of Pediatrics. Staphylococcus aureus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.678.</li><li><a class="nounderline abstract_t">Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.</a></li><li><a class="nounderline abstract_t">Rihn JA, Posfay-Barbe K, Harner CD, et al. Community-acquired methicillin-resistant Staphylococcus aureus outbreak in a local high school football team unsuccessful interventions. Pediatr Infect Dis J 2005; 24:841.</a></li><li><a class="nounderline abstract_t">Abrahamian FM, Shroff SD. Use of routine wound cultures to evaluate cutaneous abscesses for community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2007; 50:66.</a></li><li class="breakAll">Carrillo-Marquez M, Hulten K, Lamberth L, et al. Staphylococcus aureus bacteremia associated with skin and soft-tissue infection in children (abstract 2863.493). Pediatric Academic Societies Meeting, Vancouver, BC 2010.</li><li><a class="nounderline abstract_t">Malone JR, Durica SR, Thompson DM, et al. Blood cultures in the evaluation of uncomplicated skin and soft tissue infections. Pediatrics 2013; 132:454.</a></li><li><a class="nounderline abstract_t">Trenchs V, Hernandez-Bou S, Bianchi C, et al. Blood Cultures Are Not Useful in the Evaluation of Children with Uncomplicated Superficial Skin and Soft Tissue Infections. Pediatr Infect Dis J 2015; 34:924.</a></li><li><a class="nounderline abstract_t">Bryant PA, Babl FE, Daley AJ, et al. Blood Cultures in Cellulitis are not Cost Effective and Should Prompt Investigation for an Alternative Focus. Pediatr Infect Dis J 2016; 35:118.</a></li><li><a class="nounderline abstract_t">Stephens JR, Hall M, Markham JL, et al. Variation in Proportion of Blood Cultures Obtained for Children With Skin and Soft Tissue Infections. Hosp Pediatr 2020; 10:331.</a></li><li><a class="nounderline abstract_t">Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 2005; 24:622.</a></li><li><a class="nounderline abstract_t">Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005; 24:457.</a></li><li><a class="nounderline abstract_t">von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11.</a></li><li><a class="nounderline abstract_t">Chen AE, Cantey JB, Carroll KC, et al. Discordance between Staphylococcus aureus nasal colonization and skin infections in children. Pediatr Infect Dis J 2009; 28:244.</a></li><li><a class="nounderline abstract_t">Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.</a></li><li><a class="nounderline abstract_t">Gottlieb M, Avila J, Chottiner M, Peksa GD. Point-of-Care Ultrasonography for the Diagnosis of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-analysis. Ann Emerg Med 2020; 76:67.</a></li><li><a class="nounderline abstract_t">Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med 2016; 374:823.</a></li><li><a class="nounderline abstract_t">Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.</a></li><li><a class="nounderline abstract_t">Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23:123.</a></li><li><a class="nounderline abstract_t">Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med 2017; 376:2545.</a></li><li><a class="nounderline abstract_t">Gottlieb M, DeMott JM, Hallock M, Peksa GD. Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. Ann Emerg Med 2019; 73:8.</a></li><li><a class="nounderline abstract_t">Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.</a></li><li><a class="nounderline abstract_t">Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044.</a></li><li><a class="nounderline abstract_t">Chen AE, Carroll KC, Diener-West M, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 2011; 127:e573.</a></li><li><a class="nounderline abstract_t">Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44:483.</a></li><li><a class="nounderline abstract_t">Hogan PG, Rodriguez M, Spenner AM, et al. Impact of Systemic Antibiotics on Staphylococcus aureus Colonization and Recurrent Skin Infection. Clin Infect Dis 2018; 66:191.</a></li><li><a class="nounderline abstract_t">Vermandere M, Aertgeerts B, Agoritsas T, et al. Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline. BMJ 2018; 360:k243.</a></li><li><a class="nounderline abstract_t">Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015; 372:1093.</a></li><li><a class="nounderline abstract_t">Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.</a></li><li><a class="nounderline abstract_t">Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.</a></li><li><a class="nounderline abstract_t">Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999; 18:993.</a></li><li><a class="nounderline abstract_t">Vicetti Miguel CP, Mejias A, Leber A, Sanchez PJ. A decade of antimicrobial resistance in Staphylococcus aureus: A single center experience. PLoS One 2019; 14:e0212029.</a></li><li><a class="nounderline abstract_t">Khamash DF, Voskertchian A, Tamma PD, et al. Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections. J Pediatric Infect Dis Soc 2019; 8:351.</a></li><li><a class="nounderline abstract_t">Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.</a></li><li><a class="nounderline abstract_t">Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.</a></li><li><a class="nounderline abstract_t">Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.</a></li><li><a class="nounderline abstract_t">Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225.</a></li><li><a class="nounderline abstract_t">Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.</a></li><li><a class="nounderline abstract_t">Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008; 62:109.</a></li><li><a class="nounderline abstract_t">Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010; 56:283.</a></li><li><a class="nounderline abstract_t">Wang W, Chen W, Liu Y, et al. Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis. BMJ Open 2018; 8:e020991.</a></li><li><a class="nounderline abstract_t">Talan DA, Moran GJ, Krishnadasan A, et al. Subgroup Analysis of Antibiotic Treatment for Skin Abscesses. Ann Emerg Med 2018; 71:21.</a></li><li><a class="nounderline abstract_t">Williams DJ, Cooper WO, Kaltenbach LA, et al. Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections. Pediatrics 2011; 128:e479.</a></li><li><a class="nounderline abstract_t">Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777.</a></li><li><a class="nounderline abstract_t">Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51:423.</a></li><li><a class="nounderline abstract_t">Bradley JS, Antadze T, Ninov B, et al. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections. Pediatr Infect Dis J 2021; 40:238.</a></li><li><a class="nounderline abstract_t">Gee SC, Hagemann TM. Palatability of liquid anti-infectives: clinician and student perceptions and practice outcomes. J Pediatr Pharmacol Ther 2007; 12:216.</a></li><li><a class="nounderline abstract_t">Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis 2013; 56:1754.</a></li><li><a class="nounderline abstract_t">Moran GJ, Krishnadasan A, Mower WR, et al. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial. JAMA 2017; 317:2088.</a></li><li><a class="nounderline abstract_t">Hyun DY, Mason EO, Forbes A, Kaplan SL. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009; 28:57.</a></li><li><a class="nounderline abstract_t">Ham DC, Fike L, Wolford H, et al. Trimethoprim-sulfamethoxazole resistance patterns among Staphylococcus aureus in the United States, 2012-2018. Infect Control Hosp Epidemiol 2023; 44:794.</a></li><li><a class="nounderline abstract_t">Vinen J, Hudson B, Chan B, Fernandes C. A randomised comparative study of once-daily ceftriaxone and 6-hourly flucloxacillin in the treatment of moderate to severe cellulitis. Clin Drug Investig 1996; 12:221.</a></li><li><a class="nounderline abstract_t">Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther 1995; 12:139.</a></li><li><a class="nounderline abstract_t">Tack KJ, Littlejohn TW, Mailloux G, et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin Ther 1998; 20:244.</a></li><li><a class="nounderline abstract_t">Grayson ML, McDonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis 2002; 34:1440.</a></li><li><a class="nounderline abstract_t">Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002; 24:1134.</a></li><li><a class="nounderline abstract_t">Elliott DJ, Zaoutis TE, Troxel AB, et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 2009; 123:e959.</a></li><li><a class="nounderline abstract_t">Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.</a></li><li><a class="nounderline abstract_t">Talan DA, Lovecchio F, Abrahamian FM, et al. A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. Clin Infect Dis 2016; 62:1505.</a></li><li><a class="nounderline abstract_t">Hasty MB, Klasner A, Kness S, et al. Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007; 14:35.</a></li><li><a class="nounderline abstract_t">Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40:1429.</a></li><li><a class="nounderline abstract_t">Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3298.</a></li><li><a class="nounderline abstract_t">Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.</a></li><li><a class="nounderline abstract_t">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677.</a></li><li><a class="nounderline abstract_t">Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22:315.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22:S178.</a></li><li><a class="nounderline abstract_t">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a class="nounderline abstract_t">Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2016; :CD008056.</a></li><li><a class="nounderline abstract_t">Korczowski B, Antadze T, Giorgobiani M, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Pediatr Infect Dis J 2016; 35:e239.</a></li><li><a class="nounderline abstract_t">Scott LJ. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Drugs 2016; 76:1659.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. Pediatr Infect Dis J 2017; 36:486.</a></li><li class="breakAll">Dalvance (dalbavancin) package insert. Madison, NJ: Allergan USA, Inc; 2021.</li><li><a class="nounderline abstract_t">Pfaller MA, Mendes RE, Sader HS, et al. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). J Glob Antimicrob Resist 2017; 11:4.</a></li><li><a class="nounderline abstract_t">Bradley J, Glasser C, Patino H, et al. Daptomycin for Complicated Skin Infections: A Randomized Trial. Pediatrics 2017; 139.</a></li><li class="breakAll">Centers for Disease Control and Prevention.  Antibiotic Stewardship Statement for Antibiotic Guidelines – Recommendations of the Healthcare Infection Control Practices Advisory Committee https://www.cdc.gov/hicpac/Pubs/Antibiotic-Stewardship-Statement.html (Accessed on April 05, 2017).</li><li><a class="nounderline abstract_t">Steele RW, Russo TM, Thomas MP. Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children. Clin Pediatr (Phila) 2006; 45:245.</a></li><li class="breakAll">Creech, CB. Treatment of staphyococcal infections in children. Infectious Diseases in Children. November 2013 www.healio.com/pediatrics/mrsa/news/print/infectious-diseases-in-children/%7B42cabf10-e3a7-41b5-949b-044ecb4a8b7a%7D/treatment-of-staphylococcal-infections-in-children (Accessed on February 24, 2016).</li><li><a class="nounderline abstract_t">Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246.</a></li><li><a class="nounderline abstract_t">Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367.</a></li><li><a class="nounderline abstract_t">Pöyhönen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother 2017; 72:2887.</a></li><li class="breakAll">American Academy of Pediatrics. Tetracyclines. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.866.</li><li><a class="nounderline abstract_t">Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005; 330:102.</a></li><li><a class="nounderline abstract_t">Holmes L, Ma C, Qiao H, et al. Trimethoprim-Sulfamethoxazole Therapy Reduces Failure and Recurrence in Methicillin-Resistant Staphylococcus aureus Skin Abscesses after Surgical Drainage. J Pediatr 2016; 169:128.</a></li><li><a class="nounderline abstract_t">Bradley JS, Puttagunta S, Rubino CM, et al. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age. Pediatr Infect Dis J 2015; 34:748.</a></li><li><a class="nounderline abstract_t">Baker CJ. Large CA-MRSA disease burden mandates prompt diagnosis, appropriate management. AAP News 2007; 28:1.</a></li><li><a class="nounderline abstract_t">Creech CB, Al-Zubeidi DN, Fritz SA. Prevention of Recurrent Staphylococcal Skin Infections. Infect Dis Clin North Am 2015; 29:429.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Forbes A, Hammerman WA, et al. Randomized trial of "bleach baths" plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. Clin Infect Dis 2014; 58:679.</a></li><li><a class="nounderline abstract_t">Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis 2012; 54:743.</a></li><li><a class="nounderline abstract_t">Miller LG, Eells SJ, David MZ, et al. Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors. Clin Infect Dis 2015; 60:753.</a></li><li><a class="nounderline abstract_t">Al-Zubeidi D, Burnham CA, Hogan PG, et al. Molecular Epidemiology of Recurrent Cutaneous Methicillin-Resistant Staphylococcus aureus Infections in Children. J Pediatric Infect Dis Soc 2014; 3:261.</a></li><li><a class="nounderline abstract_t">Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357:380.</a></li><li><a class="nounderline abstract_t">Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316:325.</a></li><li><a class="nounderline abstract_t">McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167:709.</a></li><li><a class="nounderline abstract_t">Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987; 15:107.</a></li><li><a class="nounderline abstract_t">Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982; 97:493.</a></li><li><a class="nounderline abstract_t">Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999; 245:5.</a></li><li><a class="nounderline abstract_t">Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol 1987; 94:788.</a></li><li><a class="nounderline abstract_t">Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996; 23:1162.</a></li><li><a class="nounderline abstract_t">Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med 2005; 353:1945.</a></li><li><a class="nounderline abstract_t">Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39:1446.</a></li><li><a class="nounderline abstract_t">Hilmarsdóttir I, Valsdóttir F. Molecular typing of Beta-hemolytic streptococci from two patients with lower-limb cellulitis: identical isolates from toe web and blood specimens. J Clin Microbiol 2007; 45:3131.</a></li></ol></div><div id="topicVersionRevision">Topic 6027 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243048" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572290" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Skin and soft tissue abscesses: the case for culturing abscess fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16203945" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567987" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567988" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945667" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reversion of methicillin-resistant Staphylococcus aureus skin infections to methicillin-susceptible isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23877623" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recurrent community-associated Staphylococcus aureus infections in children presenting to Texas Children's Hospital in Houston, Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23877623" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recurrent community-associated Staphylococcus aureus infections in children presenting to Texas Children's Hospital in Houston, Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162929" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148857" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Community-acquired methicillin-resistant Staphylococcus aureus outbreak in a local high school football team unsuccessful interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572291" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Use of routine wound cultures to evaluate cutaneous abscesses for community-associated methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572291" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of routine wound cultures to evaluate cutaneous abscesses for community-associated methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23918896" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Blood cultures in the evaluation of uncomplicated skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065865" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Blood Cultures Are Not Useful in the Evaluation of Children with Uncomplicated Superficial Skin and Soft Tissue Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26741584" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Blood Cultures in Cellulitis are not Cost Effective and Should Prompt Investigation for an Alternative Focus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184289" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Variation in Proportion of Blood Cultures Obtained for Children With Skin and Soft Tissue Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999004" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of community-associated methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165132" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Discordance between Staphylococcus aureus nasal colonization and skin infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207079" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32081383" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Point-of-Care Ultrasonography for the Diagnosis of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962903" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409657" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872177" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657870" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29530658" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814879" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Methicillin-resistant Staphylococcus aureus disease in three communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846141" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339275" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243049" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020285" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of Systemic Antibiotics on Staphylococcus aureus Colonization and Recurrent Skin Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785967" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528570" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394811" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571437" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753206" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A decade of antimicrobial resistance in Staphylococcus aureus: A single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30011009" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182377" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557972" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294701" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The changing epidemiology of Staphylococcus aureus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12106956" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469106" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397923" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346539" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437689" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987525" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subgroup Analysis of Antibiotic Treatment for Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844058" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304447" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116664" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33395210" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23055856" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Palatability of liquid anti-infectives: clinician and student perceptions and practice outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23457080" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28535235" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057459" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35166197" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Trimethoprim-sulfamethoxazole resistance patterns among Staphylococcus aureus in the United States, 2012-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomised comparative study of once-daily ceftriaxone and 6-hourly flucloxacillin in the treatment of moderate to severe cellulitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10150324" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589816" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015689" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182257" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470525" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867833" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025829" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17119184" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15844065" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576834" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516395" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015695" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913766" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690270" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520144" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917519" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26758498" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Linezolid versus vancomycin for skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164462" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27766567" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28403050" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28403050" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735053" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202770" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Daptomycin for Complicated Skin Infections: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202770" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Daptomycin for Complicated Skin Infections: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708137" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708137" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680308" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103790" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical characteristics of linezolid-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578074" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Trimethoprim-Sulfamethoxazole Therapy Reduces Failure and Recurrence in Methicillin-Resistant Staphylococcus aureus Skin Abscesses after Surgical Drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25551831" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Large CA-MRSA disease burden mandates prompt diagnosis, appropriate management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26311356" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prevention of Recurrent Staphylococcal Skin Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24265356" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Randomized trial of "bleach baths" plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198793" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428411" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25844165" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Molecular Epidemiology of Recurrent Cutaneous Methicillin-Resistant Staphylococcus aureus Infections in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652653" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434444" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cellulitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420430" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A predictive model of recurrent lower extremity cellulitis in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3496278" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Incidence of erysipelas following venectomy for coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6982013" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Recurrent cellulitis after saphenous venectomy for coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10095811" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Breast cellulitis complicating breast conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3663535" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922818" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267325" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Bacterial infections in drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546080" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17609319" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Molecular typing of Beta-hemolytic streptococci from two patients with lower-limb cellulitis: identical isolates from toe web and blood specimens.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
